Crinetics Pharmaceuticals, Inc.
CRNX
$84.70
$0.260.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 25.12M | 10.73M | 6.16M | 143.00K | 1.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.12M | 10.73M | 6.16M | 143.00K | 1.03M |
| Cost of Revenue | 100.00M | 100.28M | 86.13M | 90.46M | 80.30M |
| Gross Profit | -74.89M | -89.55M | -79.97M | -90.32M | -79.27M |
| SG&A Expenses | 57.57M | 50.83M | 53.70M | 52.27M | 49.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 157.58M | 151.11M | 139.83M | 142.73M | 130.14M |
| Operating Income | -132.46M | -140.38M | -133.67M | -142.59M | -129.11M |
| Income Before Tax | -120.86M | -127.85M | -122.64M | -130.09M | -115.64M |
| Income Tax Expenses | -- | -- | 180.00K | -- | -- |
| Earnings from Continuing Operations | -120.86M | -127.85M | -122.82M | -130.09M | -115.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -120.86M | -127.85M | -122.82M | -130.09M | -115.64M |
| EBIT | -132.46M | -140.38M | -133.67M | -142.59M | -129.11M |
| EBITDA | -131.39M | -139.22M | -132.67M | -141.57M | -128.15M |
| EPS Basic | -1.14 | -1.23 | -1.29 | -1.38 | -1.23 |
| Normalized Basic EPS | -0.72 | -0.77 | -0.81 | -0.86 | -0.77 |
| EPS Diluted | -1.14 | -1.23 | -1.29 | -1.38 | -1.23 |
| Normalized Diluted EPS | -0.72 | -0.77 | -0.81 | -0.86 | -0.77 |
| Average Basic Shares Outstanding | 105.56M | 104.10M | 95.10M | 94.22M | 93.79M |
| Average Diluted Shares Outstanding | 105.56M | 104.10M | 95.10M | 94.22M | 93.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |